Clinical trials: Genital Neoplasms, Male
Metastatic Prostate Cancer
Talazoparib Plus Enzalutamide After Progression to Prior ARPi in Metastatic Prostate Cancer
The purpose of this clinical trial is to determine the anti-tumor activity of talazoparib plus enzalutamide as first line treatment for metastatic castration resistant prostate cancer (mCRPC) in participants whose disease has…
- Trial name
- TEAM PC (NCT06582628)
- Testing
- Enzalutamide capsule, Enzalutamide capsule and Talazoparib capsule
- Where
- 19 sites in France, Spain
- Volunteers
- 78 people
- Sponsor
- Fundacion Oncosur
Metastatic Prostate Cancer
Low Dose Naltrexone (LDN) for Management of Fatigue in Prostate Cancer Patients on Androgen Deprivation Therapy (ADT)
The study is being done to see if a small daily dose of naltrexone (LDN, 3 mg pill) can help reduce tiredness (fatigue) in men with prostate cancer.
- Trial name
- NCT07224009
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- University of Arkansas
Prostate Cancer, Erectile Dysfunction
A Study to Assess the Efficacy of Tadalafil to Treat Erectile Dysfunction After Radiotherapy of Prostate Cancer
This study has been designed to evaluate the efficacy and safety of a 20-mg dose of tadalafil administered "on demand" to patients with erectile dysfunction (ED) after external-beam radiotherapy (EBRT) of prostate cancer.
- Trial name
- NCT00122499
- Testing
- tadalafil
- Where
- Netherlands
- Sponsor
- Erasmus Medical Center
Prostatic Cancer, Surgical Procedure, Unspecified
Early Urinary Continence After Radical Prostatectomy: Surgical Procedure and Anatomic Landmarks
This study describes how to perform a correct prostatic apex and membranous urethra in order to preserve all anatomical elements that are necessary to achieve a very fast urinary continence after open/laparoscopic/robotic radical…
- Conditions
- Prostatic Cancer, Surgical Procedure, Unspecified, Urinary Incontinence
- Trial name
- NCT04043637
- Volunteers
- 120 people
- Sponsor
- Consorci Sanitari Integral
Androgen Independent Prostate Cancer (AIPC), Non Small Cell Lung Cancer (NSCLC)
Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004
The purpose of this study is to monitor the safety of continued DN-101 and docetaxel treatment for subjects previously enrolled in DN101-002 (ASCENT) or DN101-004 (NSCLC) Studies.
- Trial name
- NCT00285675
- Testing
- DN-101 (calcitriol) - Drug
- Where
- 13 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Novacea
Prostate Cancer
Stereotactic Body Radiotherapy vs Intensity-modulated Radiotherapy in Prostate Cancer
The primary goal of this phase II study is to compare the change of EPIC HRQOL scores (1-year minus baseline) between SBRT and IMRT.
- Trial name
- NCT02339701
- Testing
- IMRT, SBRT
- Where
- Hong Kong
- Volunteers
- 68 people
- Sponsor
- Chinese University of Hong Kong
Prostate Cancer
Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
Avodart (dutasteride) reduces the male hormone (DHT) that leads to prostate growth and stimulates cancerous growth. Avodart is currently approved by the FDA to treat men with symptoms of an enlarged prostate.
- Trial name
- NCT00805701
- Testing
- avodart
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Bay State Clinical Trials, Inc.
Prostate Cancer, Brachytherapy
PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer
PRO-BOOST-N is a prospective, multicenter, randomized phase II/III clinical trial for patients with prostate cancer and pelvic lymph node involvement (cN1M0) confirmed by PSMA PET/CT, without distant metastatic disease.
- Conditions
- Prostate Cancer, Brachytherapy, Stereotactic Body Radiation Therapy (SBRT), Dose Escalation: Solid Tumors
- Trial name
- PRO-BOOST-N (NCT07426094)
- Testing
- Ultrahypofractionated Whole-Pelvis Radiotherapy, SBRT-Based Prostate Radiotherapy (No Boost), Ablative Prostate Boost
- Where
- Poland
- Volunteers
- 600 people
- Sponsor
- Affidea Nu-med Center of Oncological DIagnostics and Therapy
Hyperandrogenism, Metabolic Cardiovascular Syndrome
Phlebotomy and Polycystic Ovary Syndrome
AIMS To study the effects of the decrease in iron tissue depots after scheduled bloodletting on insulin sensitivity, carbohydrate metabolism, classic and non-classic cardiovascular risk factors in patients with functional…
- Trial name
- NCT02460445
- Testing
- Phlebotomy, ethinylestradiol, Cyproterone Acetate
- Where
- Spain
- Volunteers
- 37 people
- Sponsor
- Manuel Luque Ramírez
Prostate Cancer
Celecoxib Compared With No Treatment Before Surgery in Treating Patients With Localized Prostate Cancer
RATIONALE: Celecoxib may be an effective treatment for early stage prostate cancer. It is not yet known if celecoxib is more effective than no treatment before surgery for prostate cancer.
- Trial name
- NCT00022399
- Testing
- celecoxib
- Where
- United States
- Volunteers
- 73 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
V-0039 is a Phase 1/2 dose escalation trial of CG7870 in combination with Docetaxel in metastatic hormone-refractory patients who have not received chemotherapy. All patients will receive docetaxel.
- Trial name
- NCT00103428
- Testing
- CG7870
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Cell Genesys
Prostate Cancer, Active Surveillance for Prostate Cancer
Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance).
- Trial name
- CHAS3 (NCT07478536)
- Testing
- Stockholm3
- Where
- Switzerland
- Volunteers
- 350 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Advanced Solid Tumor, Metastatic Solid Tumor
GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-101/GI-101A as a single agent or in combination with pembrolizumab or lenvatinib over a range of advanced and/or…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer, Urothelial Carcinoma
- Trial name
- NCT04977453
- Testing
- GI-101, Pembrolizumab (KEYTRUDA®), Lenvatinib
- Where
- 13 sites in United States, South Korea
- Volunteers
- 317 people
- Sponsor
- GI Innovation, Inc.
Prostate Cancer, Bone Metastases
A Study to Determine the Safety, Tolerability, Pharmacokinetics and Dynamic Effects of Different Doses of the Study Drug EMD 525797 in Prostate Cancer
This study is intended to test an experimental new drug called, EMD 525797 (Study Drug). This drug is not yet approved for sale and has only been tested in a small number of people to date (prior to this study starting another…
- Trial name
- NCT00958477
- Testing
- EMD 525797
- Where
- 4 sites in Belgium, Germany
- Volunteers
- 26 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Prostate Cancer
Cisplatin in Castration Resistant Prostate Cancer
It is hypothesized that treatment with cisplatin will reverse emerging refractoriness to enzalutimide in patients with CRPC by affecting AR function.
- Trial name
- NCT03275857
- Testing
- Cisplatin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of Rochester
Prostatic Neoplasms, Metastases
68Ga-PSMA PET in the Prostate Cancer
Efficacy of 68Ga PSMA PET / CT in the diagnosis of lymph node metastasis in patients with prostate cancer: a single center prospective randomized controlled trial.
- Conditions
- Prostatic Neoplasms, Metastases, PSMA-PET
- Trial name
- NCT04967001
- Testing
- PSMA PET
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Xijing Hospital
Prostatic Neoplasm
Study of Radioimmunoguided Intensity Modulated Radiotherapy (IMRT) for Prostate Cancer
The current study involves a novel and aggressive therapeutic approach for patients' prostate cancer. In addition, the investigators propose to administer hormonal therapy to patients with an especially high risk: those with…
- Trial name
- NCT00956228
- Testing
- radioimmuniguided intenstiy modulated radiotherapy
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mayo Clinic
Prostate Cancer, Hormone Refractory Prostate Cancer
Satraplatin in Hormone Refractory Prostate Cancer Patients Previously Treated With One Cytotoxic Chemotherapy Regimen
PURPOSE: The SPARC trial is designed to compare the combination of the investigational oral cytotoxic drug, satraplatin, and prednisone, versus prednisone alone as second line chemotherapy in patients with hormone-refractory…
- Trial name
- NCT00069745
- Testing
- Satraplatin, Prednisone
- Where
- 211 sites in United States, Argentina and 13 more
- Sponsor
- Agennix
Prostate Cancer
Phase I Trial of 225Ac-J591 in Patients With mCRPC
This is an open-label, single-center Phase I dose escalation study designed to determine the dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) of 225Ac-J591 in a single dose regimen.
- Trial name
- NCT03276572
- Testing
- 225Ac-J591
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Weill Medical College of Cornell University
Prostate Cancer
Spanish Urological Association Registry of Patients on Active Surveillance
Description: Multicentre observational study, not randomized. Ambispective character (retro and prospective). Opened to any member of the Asociación Española de Urología (AEU), public and private medicine.
- Trial name
- NCT02865330
- Testing
- Registry
- Where
- Spain
- Volunteers
- 946 people
- Sponsor
- Fundación Instituto Valenciano de Oncología
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.